MedPath

Quality ofrecovery with pericapsular nerve block with use of dexamethasone as an adjuvant

Not Applicable
Conditions
Health Condition 1: O- Medical and Surgical
Registration Number
CTRI/2020/11/029303
Lead Sponsor
GGS MEDICAL COLLEGE AND HOSPITA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

ASA I-III

Scheduled for Hip surgeries

Exclusion Criteria

Patientâ??s refusal to give consent.

Coagulopathy.

Infection at the injection site.

Allergy to local anaesthetics.

Severe cardiopulmonary disease (>=ASA IV) diabetic or other neuropathies .

Patients receiving opioids for chronic analgesic therapy.

Inability to comprehend visual analogue scale (VAS)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the Quality of recovery (QoR) at 24 hrs postoperatively following Pericapsular nerve group block in Levobupivacaine +dexamethasone (Group D) <br/ ><br>To assess the Quality of recovery (QoR) at 24 hrs postoperatively following Pericapsular nerve group block in Levobupivacaine +normal saline .(Group C) <br/ ><br> To Compare Quality of recovery (QoR) of both Group D and Group C. <br/ ><br>Timepoint: To assess the Quality of recovery (QoR) at 24 hrs postoperatively following Pericapsular nerve group block in Levobupivacaine +dexamethasone (Group D) <br/ ><br>To assess the Quality of recovery (QoR) at 24 hrs postoperatively following Pericapsular nerve group block in Levobupivacaine +normal saline .(Group C) <br/ ><br> To Compare Quality of recovery (QoR) of both Group D and Group C. <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
VAS will be measured at PACU , 2,4,8,12 and 24h. <br/ ><br>Cumulative opioid consumption at 24 hTimepoint: VAS at 2,4,8,12 and 24h <br/ ><br>Cumulative opioid at 24h
© Copyright 2025. All Rights Reserved by MedPath